ASBM Survey Shows Latin American Physicians Support Distinguishable Names As the annual meeting of the Drug Information Association (DIA) June 15-18 in Washington DC, John Lewis of ASBM Steering Committee member the Association of Clinical Research Organizations (ACRO) presented data from ASBM’s physician surveys. The surveys, of specialists in 11 countries from practice areas in which […]
WHO Meetings in Geneva ASBM Chairman Harry Gewanter, M.D. and International Advisory Board Chair and pharmacist, Philip J. Schneider, M.S., F.A.S.H.P., jointly presented at the World Health Organization’s (WHO) 60th International Nonproprietary Naming Stakeholders Session on April 13 in Geneva. The two provided perspectives from both a physician and pharmacist viewpoint and offered support […]
WHO Meetings in Geneva ASBM Chairman Harry Gewanter, M.D. and International Advisory Board Chair and pharmacist, Philip J. Schneider, M.S., F.A.S.H.P., jointly presented at the World Health Organization’s (WHO) 60th International Nonproprietary Naming Stakeholders Session on April 13 in Geneva. The two provided perspectives from both a physician and pharmacist viewpoint and offered support […]
Labeling Survey Released as FDA Makes First Approval On March 23, ASBM Executive Director Michael Reilly, presented at “The State of Autoimmune Disease: a National Summit” held at the National Press Club and hosted by the American Autoimmune Related Diseases Association. During his presentation, he released the findings from ASBM’s new biosimilar labeling survey that reveals […]
State Update As states are beginning their legislative sessions for the year, there are many biosimilar bills that have been introduced. ASBM supports legislation that encourages open communication between physicians and pharmacists where physicians know exactly which product is dispensed to patients. We applaud the many states that are including this important provision and […]
State Update As states are beginning their legislative sessions for the year, there are many biosimilar bills that have been introduced. ASBM supports legislation that encourages open communication between physicians and pharmacists where physicians know exactly which product is dispensed to patients. We applaud the many states that are including this important provision and […]
State Update As states are beginning their legislative sessions for the year, there are many biosimilar bills that have been introduced. ASBM supports legislation that encourages open communication between physicians and pharmacists where physicians know exactly which product is dispensed to patients. We applaud the many states that are including this important provision and […]
FDA Hosts Public Hearing on Biosimilars On January 7, ASBM members Global Colon Cancer Association (GCCA), Global Healthy Living Foundation (GHLF) and the Alliance for Patient Access (AfPA) all testified at the FDA’s Oncologic Drugs Advisory Committee (ODAC) public hearing on biosimilars. The patient groups expressed support for the pending approval, but also outlined […]
Survey Presentation at Spanish Ministry of Health On November 25, Executive Director Michael Reilly presented the European Survey results at the “1st EuropaBio – ASEBIO Meeting on Innovation and Biological Therapies” at the Spanish Ministry of Health, Social Services and Equality in Madrid. The event was hosted by EuropaBio and the Spanish Bioindustry Association (ASEBIO) and […]
ASBM Presents to WHO in Geneva On October 15, ASBM Chairman Dr. Gewanter and Executive Director Michael Reilly traveled to Geneva, Switzerland to participate in the World Health Organization’s (WHO) 59th International Nonproprietary Naming Stakeholders Session. The Geneva meeting was Dr. Gewanter’s first public appearance as ASBM Chairman, a role he assumed on September 1 […]
